Myomo to Report 4th Quarter 2025 Financial Results on Mar. 9
Digest more
Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC-4881 in familial adenomatous polyposis. The company records milestone progress across its collaborations with Sanofi and Roche/Genentech.
Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results. Read more here.
Nvidia disclosed in a filing on Tuesday that it no longer held shares in Applied Digital, drug-discovery company Recursion Pharmaceuticals, and autonomous-driving company WeRide.
Shares of Recursion Pharmaceuticals RXRX are surging Wednesday following a robust earnings report released before the bell. Recursion Pharmaceuticals stock is charging ahead with explosive momentum. What’s fueling RXRX momentum?
Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus shifted from platform integration and initial proof-of-concept to repeatability and tangible clinical/partner milestones.
Earnings ESP of RXRX: Recursion Pharmaceuticals has an Earnings ESP of 0.00% as the Most Accurate Estimate and the Zacks Consensus Estimate are both pegged at a loss of 28 cents. RXRX Zacks Rank: RXRX currently carries a Zacks Rank #2.
Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection point for the company, highlighting a first positive clinical proof-of-concept in familial adenomatous polyposis (FAP),
Nvidia sold its entire 7.71M share stake as ARK Invest bought 1.25M shares; RXRX swung 14% before closing 2% higher Wednesday.
Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry capabilities. Salt Lake City-based Recursion announced on Monday a ...
Recursion Pharmaceuticals shares were 11% higher, at $3.90, after the company reported fourth-quarter revenue that was higher than last year, and a loss that was narrower than last year's.